Atrasentan hydrochloride

盐酸阿曲生坦

Report date: 2026/03/30 20:02:02
NME

Base Information

Drug NameAtrasentan hydrochloride
Drug Alias Name阿曲生坦AtrasentanumAtrasentanXinlayVanrafia +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type A antagonists
TargetsEndothelin receptor type A
Therapy Area/IndicationsCNS Embryonal TumorDiabetes MellitusVascular Diseases +[17] 
Global Approved IndicationsProteinuriaGlomerulonephritis, IGA
Approved Indications in ChinaGlomerulonephritis, IGA
Original Approved Country/TerritoryUnited States
Original Approved Date2025/04/02
Country/TerritoryCzechiaBelgiumCanada +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesIqvia Rds (Shanghai) Co LtdNovartis Pharma Schweiz AgNovartis Pharma Ag +[7] 
Inactive CompaniesAbbott LaboratoriesNational Institutes Of HealthNational Cancer Institute +[5] 
Active IndicationsProteinuriaGlomerulosclerosis, Focal SegmentalGlomerulonephritis, IGA +[5] 
Inactive IndicationsCNS Embryonal TumorDiabetes MellitusVascular Diseases +[12] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG